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Summary
OBJECTIVES: Several studies have reported prolonged
QTc intervals in patients under methadone maintenance
treatment, including development of torsade-de-pointes ar-
rhythmia and death. It is still not clear why some patients
develop critical QTc extensions while others do not.
METHODS: ECG findings in a convenience sample of
210 methadone-maintained heroin-dependent patients, tak-
ing HCV-infection status and methadone dosage into ac-
count simultaneously by means of a multiple linear regres-
sion model with QTc-interval as the dependent variable.
RESULTS: Prolonged QTc-time is associated with hepat-
itis C infections (p = 0.005) and higher doses of racemic
methadone (p = 0.012).
CONCLUSION: Infection with hepatitis C increases the
likelihood of critical QTc prolongation in patients in meth-
adone maintenance treatment.
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Introduction
Methadone maintenance treatment is the best-evaluated
therapy for heroin dependence, and its effectiveness in re-
taining patients in treatment and in reducing consumption
of street-heroin has been demonstrated by a great number
of studies [1]. Methadone is also prescribed for the man-
agement of pain to many patients in the Americas, Aus-
tralia and Europe [2].
Methadone – as with many other drugs – blocks the human
Ether-à-go-go Related Gene (hERG) voltage gated potassi-
um channel in the heart [3]. This blockade results in
delayed re-polarisation [4] that can be seen as QT interval
prolongation in the ECG. A prolonged QT interval is asso-
ciated with an elevated risk of life-threatening cardiac ta-
chyarrhythmias called torsades-de-pointes.
QT prolongations and torsades-de-pointes in patients on
methadone have been increasingly reported since its first
description by Krantz and colleagues [5]. There is no clear
evidence of whether methadone doses (or its blood-levels)
and QT times are inter-related [6–12].
Chronic hepatitis C virus (HCV) infection is common in
patients under methadone substitution treatment [13, 14].
Extra-hepatic manifestations of hepatitis C may also in-
clude the myocardium. Hepatitis C related cardiomyopath-
ies – dilated and hypertrophic cardiomyopathy due to
chronic myocarditis – have been described in several stud-
ies [15–18]. The hepatitis C core protein inhibits several
signal proteins in myocytes of mice. HCV is presumed
to replicate within myocardial tissue. Successful anti-viral
therapy of HCV is supposed to improve HCV related car-
diomyopathy. The frequency of HCV related cardiomy-
opathy seems to vary between different regions and popu-
lations [18].
To our knowledge, only one study has so far reported a
correlation between HCV infection and prolonged QT in-
terval in HIV-infected patients [19]. The presence of liver-
cirrhosis or markers of impaired liver function like lower
prothrombin activity or lower serum concentrations of al-
bumin, elevated bilirubin or plasma bile salt levels has
also predicted prolonged QTc-time independent of aeti-
ology [20]. Furthermore, a study on QTc-length among
methadone-maintained former injection drug users found
impaired liver-function – as measured by prothrombin-
levels – to negatively influence QT-time, synergistically to-
gether with hypokalaemia and co-medication that inhibit
CYP3A4 function [21].
Thus, since there is some evidence that HCV-infection
might contribute to prolonged QTc-times in methadone-
maintained patients, we assessed cardiac activity in a large
sample of methadone-maintained patients, taking account
of their HCV-status.
Methods
ECG-registration was performed in a supine position with
a Cardiette ar1200 view instrument (12-lead ECG). QT-in-
tervals were measured manually all by the same physician
using a lead II as long as T-wave morphologic characterist-
ics were distinct. Otherwise a lead V5 was used [22]. The
T-wave endpoint was defined by the tangent method (inter-
section of a line extrapolated from the iso-electric baseline
and the tangent line, which touches the terminal part of the
T wave at the point of maximum down-slope). To account
for potential arrhythmias, RR-intervals were measured at
three different time points of the ECG and the mean value
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was then used for the calculation of QTc-time. QTc-values
were calculated according to Bazett’s formula [23].
The following variables with a potential influence on QTc-
time at the time of ECG-recording were entered as cov-
ariates into the analysis: Continuous covariates were age
(years) and daily methadone dosage (mg). In accordance
with the study by Kornick et al. [24], the log of daily meth-
adone dosage was entered into the analysis, to account for
skewed distribution of untransformed data. Categorical co-
variates were sex (male/female), and the presence or ab-
sence of alcohol-dependence (ICD-10; F10.2x), cocaine
dependence (ICD-10; F14.2x), and infections with HBV,
HCV, and HIV. Furthermore, a binary variable indicating
whether a patient was receiving any additional medications
with a potential for QT-prolongation (according to the list
on http://www.qtdrugs.org; accessed on the 15/09/2011)
was entered into the calculations.
HCV-status was categorised as follows: HCV+/RNA+
(presence of HCV-antibodies/observed viral load), HCV+/
navl (no viral load at the time of ECG registration, but viral
load in former analyses), HCV+/AB (diagnosis only by ob-
servation of antibodies; HCV-RNA-determination not (yet)
done), HCV- (HVC negative), and unknown HCV-status.
Sample, setting and data analysis
A total of 219 patients, willing to participate, were in meth-
adone maintenance treatment (MMT), and 218 of them had
had at least one ECG-screening between March 2007 and
October 2008, thus meeting inclusion criteria. Exclusion
criteria were any cardiac diseases according to the medic-
al files (n = 8). The final sample consisted of 210 patients.
Patients’ characteristics are listed in table 1.
The study was cross-sectional and took place in an outpa-
tient facility of the Psychiatric University Hospital in the
centre of Zurich, Switzerland, specialised in the treatment
of substance use disorders. All patients on opioid mainten-
ance treatment (N = 301) were approached by the research
team, and the aim of the study was carefully explained. A
total of 260 patients consented to participate. The ethic’s
commission of the canton of Zurich agreed with the study
procedures.
Zero-order associations between independent variables and
QTc were analysed by t-test for categorical covariates and
by Pearson correlations for continuous covariates. Associ-
ations with p <0.05 were considered significant and cor-
responding variables were entered as predictors into a mul-
tivariate linear regression model with QTc as the dependent
variable.
The model was represented by the formula
(i= 1 to 210), where:
yi = observed QTc-value (msec) of ith patient, c = constant
(msec), xi1= belonging of ith patient to the group “HCV+/
RNA+” (no = 0, yes = 1), xi2 = methadone dose (log(mg/
d)) of ith patient, b1 = regression coefficient of x1, b2 = re-
gression coefficient of x2, εi = error of estimated QTc for ith
patient (difference between estimated and observed value).
We used OLS method for parameter estimation.
Data-analysis was done with PASW Statistics (version
18.0; IBM Corp., Sumers, NY).
Results
Patients’ characteristics
A total of 151 (71.6%) patients were male and the mean
age was 37.06 years. In the sample, 127 (60.5%) suffered
from an additional cocaine-dependence and 46 (21.9%)
from alcohol-dependence. A total of 96 (45.7%) patients
had one or several prescribed medications with a QT-pro-
longing potential. 58 (27.6%) were HBV-positive, and 83
Table 1: Number of patients, means and standard deviations of QTc-time, and corresponding p-values of zero-order associations.
Categories: n mean QTc (ms) SDg p-value
Sex: male:
female:
151
59
442.7
445.6
30.4
29.4
0.532a
Cocaine-dependence: yes:
no:
127
83
445.9
439.9
31.2
28.2
0.156a
Alcohol-dependence: yes:
no:
46
164
447.2
442.5
28.6
30.5
0.351a
Medication with QT-prolongation yes:
no:
96
114
445.8
441.7
33.4
27.0
0.334b
HBV: positive:
negative:
unknown:
58
83
69
442.6
445.0
442.5
27.3
31.9
30.5
0.646a
0.849d
HIV: positive:
negative:
unknown:
14
153
43
451.3
444.7
437.0
22.1
31.3
27.5
0.443a
0.206d
HCV: HCV+/RNA+:
HCV+/navl:
HCV+/AB:
HCV-:
unknown:
53
17
30
101
9
453.5
453.6
443.2
437.6
433.8
25.7
25.3
32.9
31.1
25.7
0.009d
0.020f
n mean SDg re
Age [y]: 210 37.0 8.0 0.13
Methadone dosage [mg]: 210 113.6 80.6c 0.188**
Methadone dosage [log]: 210 1.94 0.33 0.162*
a t-test with equal group variances; b t-test with unequal group variances; c significant deviation from normal distribution; d one-way ANOVA; e Pearson correlation
coefficient; f post-hoc test (Scheffé); g standard deviation
* p <0.05; ** p <0.01
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(39.5%) were HBV-negative, whereas 69 (32.9%) patients
had an unknown HBV-status. 14 (6.7%) patients were HIV-
positive and 153 (72.9%) were HIV-negative, whereas 43
(20.5%) had an unknown HIV-status.
A total of 53 (25.2%) patients were diagnosed with HCV+/
RNA+; 17 (8.1%) were HCV+/navl, 30 (14.3%) were
HCV+/AB, 101 (48.1%) were HCV- (HVC negative), and
9 patients (4.3%) had an unknown HCV-status. One-way
ANOVA showed significant differences of mean QTc-val-
ues between these groups (F = 3.99; df = 3; p = 0.009).
Post-hoc procedure according to Scheffé (assumed homo-
geneity of between-group variances; Levene-Statistics:
1.41; df1 = 3; df2 = 197; p = 0.23) revealed a significant
difference between the HCV+/RNA+ and HCV-groups (p
= 0.02).
Mean daily methadone dosage was 113.6 mg and distri-
bution differed significantly from normal distribution
(Kolmogorov-Smirnnov: Z = 2.63; p <0.001) whereas the
distribution of the log of daily methadone dosage did not
(Kolmogorov-Smirnnov: Z = 1.02; p = 0.25). QTc-values
were normally distributed (Kolmogorov-Smirnnov: Z =
0.49; p = 0.96) and mean QTc-time was 443.5 ms (SD =
30.1). No relevant arrhythmic events were detected in the
ECGs done for this study.
Covariates of QTc-values
As shown in table 1, among all considered variables only
the daily methadone dosage and HCV+/RNA+ status were
correlated significantly with QTc-time. The log of daily
methadone dosage and HCV+/RNA+ were not signific-
antly associated with each other (Spearman’s Rho =
–0.021; p = 0.76) and were therefore entered into a multiple
linear regression model with QTc as the dependent vari-
able. A total of nine patients with unknown HCV-status
were omitted from this analysis. The result (table 2) was
an overall significant model (n = 201; F = 6.979; df = 2; p
= 0.001), predicting QTc-values with an adjusted R-Square
of 0.06. Both regressors showed similar standardised ef-
fects prolonging QTc (HCV+/RNA+ (yes/no): β = 0.195;
p = 0.005; methadone dosage (log mg/d): β= 0.174; p =
0.012). The regression line intercept (constant) was 409.7
msec.
Discussion
An infection with hepatitis C-virus is correlated with a
longer QTc-interval in heroin dependent patients who are
maintained on methadone. To our knowledge, our study
is the first to report this association. We also found the
dosage of methadone to be a predictor of QTc-times, but
to a slightly lesser degree. This might partially explain the
discrepancy of results from studies on the link between
methadone dose and QTc-times [12, 25–28]. The presence
of an HCV-infection in a patient might point to a more
severe course of the disorder of compulsive heroin use.
Thus, HCV-carriers might need higher-dosages of methad-
one, confounding the influence of HCV-status and dosage-
level on cardiac action, even though that was not the case
in our study.
Furthermore, the current study showed that the presence
of viruses is needed for HCV infection to prolong cardiac
re-polarisation and that antibodies alone do not seem to
have this effect. There seems to be little knowledge about
the cardiac consequences of an HCV-infection. The poten-
tial patho-mechanisms for our findings need further elucid-
ation. Both, hepatitis C induced myocarditis causing QT
prolongation or indirect effects, involving impaired liver
function, have to be considered.
The current study has several shortcomings that deserve
mentioning. Due to the cross-sectional design of our study,
nothing can be said about the stability of the QTc-time as-
sessed at one time point.
Furthermore, we were unable to determine the specific type
of hepatitis C virus or the genes of the major histo-compat-
ibility complex class II. These genes may influence the de-
velopment of different phenotypes of HCV cardiomyopath-
ies [18].
Measures of liver-function like prothrombin or other liver
enzymes would have been helpful for elucidating the path-
way by which HC-viruses influence cardiac action.
However, since our result of HCV contribution to pro-
longed QT-time was unexpected, we did not systematically
determine these values. Furthermore electrolyte measures
as additional factors influencing QT time were not
routinely assessed and the ECG interpreter was not blinded.
It would have been interesting to compare QTc-times in
HCV-infected patients before and after successful treat-
ment. However, we only had this data in a small sample of
patients not allowing statistical evaluation. Therefore, fur-
ther studies are needed to replicate our findings in other
samples and to evaluate the influence of different HC-virus
strains and of successful treatment of HCV-infections.
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